Compare Ascendis Pharma A/S (ASND) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Match Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Match Group Inc trades at $39.87 (market cap $9.06B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Match Group Inc pays a 2.06% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MTCH | |
|---|---|---|
Market Cap | $17.74B | $9.06B |
Sector | Health | Media |
52-Week High | $277.18 | $39.32 |
52-Week Low | $163.32 | $28.90 |
Enterprise Value | $18.11B | $12.01B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MTCH trades at $38.85, down 1.2% today, with a bullish technical signal from moving averages and key support at $38. The company shows solid fundamentals with a P/E of 14.83, net income margin of 18.83%, and three consecutive quarterly earnings beats. Revenue growth remains stable at $3.49B for 2025, while cash flow from operations improved to $1.08B. Recent news highlights a turnaround focus, including Tinder's AI features and Hinge's growth.
The outlook is positive with a consensus price target of $41.63, implying 7% upside. Analyst sentiment is bullish (53% Buy), but risks include high long-term debt of $3.85B and competitive pressures in dating apps. Earnings growth and debt management are critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
